Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-09-17 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - NTI 4 pages 15.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Neurotech International Limited. It includes specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement related to changes in the company's issued securities, specifically the expiry of options. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of changes in securities. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation of securities.
2024-09-17 English
Application for quotation of securities - NTI 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, issue price, and the class of securities. It is not a financial report, earnings release, or management discussion, but rather a formal announcement related to capital changes and securities quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change announcements.
2024-09-16 English
Ceasing to be a substantial holder 2 pages 178.6KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001, detailing changes in relevant interests and associations of a substantial shareholder in Neurotech International Limited. It reports changes in shareholdings and relevant interests but does not contain financial statements, management discussion, or other report content. This type of filing is a notification of changes in major shareholding levels, fitting the definition of Major Shareholding Notification (MRQ). The document length is 4392 characters, which is consistent with a detailed notification rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2024-09-16 English
Becoming a substantial holder 3 pages 210.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001 Section 671B. It details the substantial shareholding and relevant interests of Biotech Capital Management Pty Ltd and related entities in Neurotech International Limited as of 13 September 2024. The content focuses on shareholding disclosures and voting power, which aligns with notifications of major shareholding changes. There is no financial performance data, management discussion, or other report content. Therefore, this document fits the category of Major Shareholding Notification (MRQ). The document length and detail support a confident classification.
2024-09-16 English
Results of General Meeting 2 pages 101.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 10 September 2024, titled 'Results of General Meeting'. It details the outcomes of shareholder votes on various resolutions at a General Meeting, including proxy votes and poll results. The content focuses on the official results of shareholder voting rather than the meeting materials, presentations, or the meeting itself. The document is relatively short (4230 characters) and is clearly an announcement of voting results. Therefore, it fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2024-09-09 English
NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children 4 pages 176.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 September 2024 from Neurotech International Limited. It details the results of a Phase I/II clinical trial (NTIPANS1) of the drug NTI164 in children with PANDAS/PANS, focusing on proteomic and genomic analysis and clinical benefits observed. The content is scientific and clinical trial results oriented, not a financial report or earnings release. It is not a regulatory filing or a brief announcement but a detailed clinical trial result announcement. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any financial statement. It is also not a management or board change announcement, nor a capital or financing update. The document is a detailed announcement of clinical trial results and scientific findings, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific financial or corporate filing categories.
2024-09-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.